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QUESTIONASKED: Centers forMedicare andMedicaid Services (CMS) ismaking small
adjustments to physician reimbursement to improve the value of care delivered to
Medicare beneficiaries under fee-for-service. Using localized prostate cancer as a
model, we examined whether these small reimbursement changes were enough to
increase the value of cancer care.
SUMMARY ANSWER: Small variations in fee-for-service reimbursement for costly
physician-administered prostate cancer drugs in the early 2000s did not reduce low-value
care, suggesting that small payment changesmaynot be enough tomotivate improvements
in care quality. Moreover, patient clinical characteristics and practice organization were
associated with low-value care (Table 3).
METHODS: We conducted a natural experiment exploiting unintended differences in
regionalMedicare carriers’ payment of Part B drug claims.Using data fromSEER registries
that are linked to Medicare claims, we conducted multilevel analysis to assess whether the
reimbursement variation affected urologists’ inappropriate use of gonadotropin-releasing
hormone (GnRH) agonists. These drugs are often used, and misused, in prostate cancer
treatment.
BIAS, CONFOUNDING FACTOR(S), DRAWBACKS: We conducted our study among
urologists. Much of cancer care is delivered by medical and radiation oncologists and our
results may not be generalizable to these providers. Future studies should address these
groups specifically to compare how reimbursement changes, both small and large, affect
prescribing of GnRH agonists to complete our understanding of the clinical and practice
contexts in which reimbursement does or does not change clinical decision making.
REAL-LIFE IMPLICATIONS: CMS’ efforts to align reimbursementwith high quality care
should continue. However, our findings suggest that small adjustments to reimbursement
on the order of 2% to 3% may be insufficient to improve the value of care delivered by
urologists treating localized prostate cancer. Other efforts may also be needed to change
physicians’ behavior, such as CMS’ identification of low-performing practices through
publication of quality ratings and targeted, physician-centered interventions to support
health care providers who are not adherent to guidelines.
The full version of this article
may be viewed online at
DOI: 10.1200/JOP.2015.007344
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Table 3. Multilevel Regression Predicting Primary
GnRH Agonist Use
Factor Odds Ratio 95% CI
Reimbursement generosity
index
1.00 1.00 to 1.00
Practice type
Group practice Reference
Solo practice 1.27 1.07 to 1.52
Missing 0.86 0.58 to 1.26
Physician prostate panel size,
prostate patients per year
, 20 Reference
21-37 0.75 0.65 to 0.86
$ 38 0.81 0.68 to 0.96
T stage
T1 Reference
T2 1.91 1.72 to 2.13
Grade
Well differentiated, 2-4 Reference
Moderately differentiated, 5-7 2.26 1.78 to 2.88
Missing 3.50 2.50 to 4.91
No. of comorbidities
0 Reference
1 1.40 1.24 to 1.57
2 1.43 1.18 to 1.72
$ 3 2.07 1.65 to 2.60
Age, years 1.78 1.38 to 2.30
Age, squared 1.00 1.00 to 1.00
Race/ethnicity
Non-Hispanic white Reference
Non-Hispanic black 1.42 1.17 to 1.73
Hispanic 1.25 1.00 to 1.56
Other 1.30 0.94 to 1.79
Missing 1.95 1.50 to 2.53
Radiation oncology consultation
No Reference
Yes 0.26 0.23 to 0.31
Medical oncology consultation
No Reference
Yes 0.88 0.65 to 1.19
Urology consultation
No Reference
Yes 5.62 3.19 to 9.90
(continued in next column)
Table 3. Multilevel Regression Predicting Primary
GnRH Agonist Use (continued)
Factor Odds Ratio 95% CI
Primary care consultation
No Reference
Yes 0.41 0.36 to 0.46
Constant 0.95 0.87 to 1.04
NOTE. Sample includes only patients (n = 15,128) of urologists who
prescribedGnRHagonists. Themodel alsoadjusts for urologists’ length
of time in practice, sex, training location, board certification status,
medical school affiliation, proportion of minority patients in practice,
patients’ marital status, rural residence, community educational
attainment, community income, prior primary care use, year treated,
and SEER region.
Abbreviation: GnRH, gonadotropin-releasing hormone.
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Abstract
Purpose
The Centers for Medicare and Medicaid Services recently initiated small reimbursement
adjustments to improve the value of care delivered under fee-for-service. To estimate the
degree to which reimbursement influences physician decision making, we examined
utilizationof gonadotropin-releasinghormone (GnRH)agonists amongurologists asPartB
drug reimbursement varied in a fee-for-service environment.
Methods
We analyzed treatment patterns of urologists treating 15,128 men included in SEER-
linked Medicare claims who were diagnosed with localized prostate cancer between
January 1, 2000, and December 31, 2003. We calculated a reimbursement generosity
index to measure differences in GnRH agonist reimbursement among regional Medicare
carriers and over time. We used multilevel analysis to control for patient and provider
characteristics.
Results
Among urologists treating early-stage and lower grade prostate cancer, variation in
reimbursement was not associated with overuse of GnRH agonists from 2000 to 2003, a
period of guideline stability (odds ratio, 1.00; 95% CI, 0.99 to 1.00).
Conclusion
Small differences in androgen-deprivation therapy reimbursement generosity were not
associated with differential use. Fee-for-service reimbursement changes currently being
implemented to improve quality in fee-for-service Medicare may not affect patterns of
cancer care.
INTRODUCTION
Numerous payment policies and incen-
tives have been implemented to increase
the value of cancer services in the United
States.1,2 Although recent attention has
focused on alternative payment models,3
the majority of oncology care continues
to be delivered under fee-for-service
arrangements.4,5 Accordingly, the Cen-
ters for Medicare and Medicaid Services
(CMS) recently announced plans to link
value or quality to 90% of Medicare
fee-for-service payments by 2018.5
Beginning this year, CMS will adjust
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reimbursement to disincentivize poor-quality and high-
cost care.3,5
These plans were likely informed by prior evidence of
the impact of reimbursement reductions on prostate cancer
care delivery in the past decade. Before 2005, whenMedicare
had a generous reimbursement policy for gonadotropin-
releasing hormone (GnRH) agonists and other physician-
administered drugs reimbursed through the Part B medical
benefit, this form of androgen-deprivation therapy (ADT)
was widely used as primary treatment of localized prostate
cancer,6-10 despite the lack of recommendation by published
guidelines for patients with early prostate cancer.11,12 A
sharp decline in GnRH use occurred after 2005, when the
Medicare Modernization Act (MMA) of 2003 changed the
pricing benchmark used in the reimbursement formula from
an average wholesale price set by the manufacturers to
average sales price on the basis of national sales, reducing
reimbursement for GnRH agonists by 65%.7,8,13,14 These
studies suggest quality may be improved by limiting
reimbursement of inappropriate treatment options. How-
ever, no prior study has evaluated the effect of more modest
reimbursement variationon clinical decisionmaking, similar to
the 0.5% to 1% reductions in payments currently in place to
transform fee-for-service.15
Between January 2000 and December 2003, there were
unintentional differences in physician reimbursement for
GnRH agonists delivered through the Medicare Part B drug
benefit,16 which resulted in reimbursement variations of up
to 10.5%, or $59 per administration, across providers.
Taking advantage of this natural experiment, we examine
the association between modest reimbursement variation
and GnRH agonist use during a period in which there was
stability in guidelines (primary ADT recommended for
high-risk, but not low- or intermediate-risk, patients) and
the potential harms of ADT were largely unknown. We
hypothesize that practicing under more generous drug
reimbursement conditions is associated with greater use of
ADT.
METHODS
We conducted a retrospective analysis to examine the asso-
ciation of reimbursement and primary GnRH agonist use
among patients with clinically localized prostate cancer. The
study was approved by the University of North Carolina at
Chapel Hill Institutional Review Board.
Data Sources
We linked SEER-Medicare data to the American Medical
Association (AMA) Masterfile. SEER records patient
demographics, tumor morphology, and stage at diagnosis for
a population-based sample of US residents diagnosed with
cancer.17 Medicare administrative claims include hospital
services, physician services, and physician-administered drug
therapy. We used Medicare Provider Analysis and Review,
Outpatient, Durable Medical Equipment, and Carrier files for
sample selection, initial treatment ascertainment, and treating
provider identification; we used carrier files alone to evaluate
response to reimbursement because other files do not identify
physicians and/or reimbursement.18 AMA Masterfile data
include individual and practice characteristics from
approximately 800,000 US physicians. Data originate from
training records collected annually (96% to 98% response
rates) and are supplemented by physician survey.19
Cohort Definitions
Patients
We identified patients with an incident diagnosis of prostate
adenocarcinoma as their first and only cancer. Of men
receiving initial treatment between January 1, 2000, and
December 31, 2003, we excluded those # 66 years old at
diagnosis because we could not ascertain their comorbidities.
We also excludedpatientswhose initial treatment could not be
fully ascertained because they were diagnosed at autopsy, by
death certificate, or at a nursing/convalescent facility; died
within 12months of diagnosis; were not continuously enrolled
in fee-for-service Medicare for 12 months before and after
diagnosis; or had no treatment claims. This study focused on
patients with early prostate cancer, so we restricted the cohort
to men who lacked evidence of nodal or metastatic
involvement andwhohadno greater than stageT2 tumors and
WHO grade 1 or 2 disease.8 We also excluded men with an
actuarial life expectancy of less than 5 years because national
guidelines permitted primary ADT use for these patients.6,11
Urologists
We included only urologists because they prescribe 95%of the
GnRH agonists used among patients with localized prostate
cancer.20 We used patients’ medical claims to identify the
treating provider, defined as the physician responsible for the
most treatment claims.21 Providers were matched by
encrypted Unique Physician Identifier Number or National
Provider Identifier to the AMAMasterfile data. We excluded
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urologists who did not prescribe GnRH agonists because we
could not compute their reimbursement generosity index
(RGI; see Measures).
Measures
Dependent variable
PrimaryGnRHagonist use is defined as any claim for goserelin
acetate (GA) implants, leuprolide acetate (LA) injections, LA
implants, or triptorelin pamoate injections administered
within 1 year after diagnosis, unless orchiectomy, radical
prostatectomy, brachytherapy, chemotherapy, or cryotherapy
was also administered within that time (codes used listed in
Appendix Table A1, online only).
Explanatory variables
Part B claims are paid by local carriers, which lack uniform
reimbursement policies.22 From 1997 to 2002, carriers were
responsible for translating Part B drug Healthcare Common
Procedure Coding System (HCPCS) claims into National
Drug Code (NDC) indices.18 Although some HCPCS codes
had only one equivalent NDC, others had $ 10 matches,
resulting in substantial reimbursement variation.16 In addi-
tion to variability among carriers, reimbursements changed at
different rates over time as a result of changes in average
wholesale prices for specific NDCs.18
Thus, for each urologist, we created an RGI, a weighted
average difference in reimbursement indicating reimbursement
above or below the national average.18 First, we calculated the
difference between the reimbursement the physician re-
ceived for each ADT modality and the average national
reimbursement amount for that same product during that
time period. Next, we weighted these differences by the
proportion of spending on that drug among spending on all
GnRH agonists used by each urologist in that year (Appendix,
online only). Differences in RGI reflect reimbursement var-
iation specific to each carrier and over time, as well as changes
in the mix of drugs prescribed by each physician in any year.
An RGI greater than 0 indicates excess reimbursement
(greater than the national average).
The following example demonstrates our calculation of
RGI.Aphysicianstarted fivepatientsonADTin2001,usingLA
injections one time and GA implants four times. During that
year, he was reimbursed for LA at $592.60 per monthly dose.
Hewas reimbursed forGAat $446.49permonthlydose all four
times. Thus, in 2001, his average reimbursement for LA was
$592.60 and his average reimbursement for GA was $446.49.
However, across all SEER regions, the average reimbursement
in 2001 for LAwas $487.92 and the average reimbursement for
GAwas $434.70. Thus, he was reimbursed $104.68 more than
the SEER national average for LA and $11.79 more than the
SEER national average for GA. In 2001, LA spending was 43%
of spending on all initial use of primary ADT andGAwas 55%
of all spending on initial use of primary ADT. This doctor’s
reimbursement generosity was proportional to only the two
drugs he used. Over 2001, this physician’s RGI is equal to:
ð592:602 487:92Þ þ ð446:492 434:70Þ0:545
0:434þ 0:545 ¼ 52:9
Thus, for this physician in 2001, his reimbursement per
monthlydosewas$53moregenerous thanthenationalaverage
for the mix of GnRH agonists he used.
Control variables
We controlled for patient, urologist, and practice variables (see
Appendix,onlineonly)knowntobeassociatedwithprostate treat-
ment decisions, quality of care, or responsiveness to incentives.
Statistical and Sensitivity Analyses
Asaresult ofhigh intraclass correlationamongpatients treated
by the same urologist23 and to exploit both increases and
decreases in reimbursement as well as reimbursement var-
iation bothwithin physicians and between physicians,we used
multilevel mixed effects logistic regression models to control
for clustering. Statistical significance was evaluated at a = .05
using Stata/SE 12.1 (StataCorp, College Station, TX).24
We varied definitions of the primary dependent (GnRH
agonist use) and independent variables (treating provider) to
assess robustness of our findings.Because reimbursementmay
affect adjuvant GnRH agonist use, we created a second
dependent variable that captured both primary GnRH agonist
use(potentially inappropriate)andadjuvantGnRHagonistuse
(potentially appropriate). Further sensitivity analysis used the
SEER average reimbursement for urologists who did not
prescribe any GnRH agonists to assess the effect of excluding
nonprescribing urologists.
RESULTS
The final sample (AppendixFig A1) included 15,128menwith
T1 or T2 well-differentiated or moderately differentiated
prostate cancer treated by 1,800 urologists between 2000 and
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2003. Twenty four percent of patients (3,653 of 15,128
patients) received primary ADT.
GAimplants(3.6mg)andLAinjections(7.5mg)composed
more than 94% of ADT use. Monthly median reimbursement
for GA implants (3.6 mg), which had one equivalent NDC,
fluctuated little from 2000 to 2003, increasing from $193 to
$199. Reimbursement for LA injections (7.5 mg), which
had multiple NDCs, had greater variation; the median
reimbursement per monthly dose was $207 in 2000, $214 in
2001, $190 in 2002, and $223 in 2003.
The average RGI over the study period was 2.93 (standard
deviation [SD], 69.63), indicating that, on average, urologists
treating patients with primary GnRH agonists were reim-
bursed $2.93 more generously for the drugs they used relative
to the national average reimbursement. However, RGI
fluctuated by treatment year; the averageRGI decreased from
2.92 in 2000 to 1.88 in 2001, increased to 3.89 in 2002, and
decreased to 2.87 in 2003, with the average RGI ranging from
$18.89 less than the average reimbursement at the 25th
percentile to $15.03more than average at the 75th percentile.
However, variation between urologists (SD, $73.63) was
greater than variation among individual urologists over time
(SD, $43.54).
Primary GnRH agonist use grew from 21.9% of patients in
2000 to 29.2% in 2002 and then decreased to 23.1% in 2003
(Table 1). Patients of physicians who were reimbursed for
GnRH agonists at levels above the national average differed
from those of physicians whowere reimbursed at or below the
national average on most clinical, demographic, care-seeking,
andgeographic indicators (Table 1).However, at the physician
level, 30% of patients treated by physicians practicing in areas
where GnRH agonist reimbursement is at or below national
average received primary ADT; this proportion is identical
for physicians reimbursed above the national average (30%;
P = .56; Table 2).
After controlling for patient, urologist, and practice
characteristics, excess GnRH agonist reimbursement was not
associated with primary GnRH agonist use among patients
with T1 and T2 well-differentiated or moderately differ-
entiatedprostate cancer (odds ratio [OR], 1.00; 95%CI, 1.00 to
1.00; Table 3). Solo practitioners were more likely to use
primaryADT thanurologists in grouppractice orwithmissing
practice status, all else being equal (OR, 1.27; 95% CI, 1.07 to
1.52). Larger panel sizes and seeing a primary care provider
between diagnosis and treatment were protective against
primary GnRH agonist use.
Sensitivity Analyses
Results for all models were substantively similar when we also
included adjuvant GnRH agonist use in the outcome (data not
shown).When considering all urologists (2,213 urologists and
16,789 patients) and assuming nonprescribers were reim-
bursed at the SEERnational average, excessive reimbursement
had a small negative effect onGnRHagonist overuse, although
the upper CI rounded to 1 (OR, 0.99; 95% CI, 0.99 to 1.00).
DISCUSSION
We evaluated the potential association between small
reimbursement variation and use of primary ADT for
patients with early prostate cancer during a period when there
was widespread variation in reimbursement across different
regions of the United States. Contrary to our hypothesis, we
found no association between variation in reimbursement
and primary GnRH agonist use, suggesting that small
incentivesordisincentivesmayhave little impactonurologists’
prescribing practices.
Our findings were consistent with other studies exploiting
variation in carrier reimbursement. For example, small carrier
reimbursement differences were not associated with use of
chemotherapy among fee-for-service Medicare beneficiaries
with metastatic cancer during the 1990s.18 However, our
findings differ from prior studies that demonstrated a
sharp decline in GnRH agonist use after the 2005 MMA
reimbursement changes.7,8 One possibility for the divergent
findings is confounding in studies conducted in the mid-
2000s.25-27 Coincident with MMA reimbursement changes,
many other events occurred that could have contributed to the
decline in GnRH agonist use; for example, emerging evidence
about harms, guideline changes, prosecution of illegal
marketing practices, and practice reorganization.11,12,26,28-34
In fact, further analyses related to large changes in ADT use
coincident with MMA reimbursement cuts suggest that
factors other than financial incentives may have played a
role35; urologists may not have responded uniformly to
reimbursement cuts6; and, in some clinical indications,
physicians were responsive to changes in evidence to omit
GnRH agonists despite high reimbursement.36 Thus, the
relationship between reimbursement and physician decision
making may be less well understood than previously thought.
Future research should attempt to isolate the independent
impact ofmultiple changes onGnRHagonist use, in particular
the effect of widespread practice reorganization occurring in
response to new technologies. We purposely designed this
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Table 1. Patient Characteristics According to Reimbursement Generosity Index of Urologists Prescribing GnRH Agonists
Characteristic Overall (N = 15,128)
GnRH Agonist
Reimbursement
Less Than or Equal to
National Average
(n = 5,932)
GnRH Agonist
Reimbursement
Greater Than
National Average
(n = 9,196) P
GnRH agonist overuse 3,653 (24.1) 1,356 (22.9) 2,297 (25.0) .003
Reimbursement generosity index, mean (SD) 2.9 (69.6) 248.0 (65.6) 35.8 (49.5) , .001
Year treated , .001
2000 3,317 (21.9) 1,332 (22.5) 1.985 (21.6)
2001 3,894 (25.7) 1,618 (27.3) 2,276 (24.7)
2002 4,421 (29.2) 1,890 (31.9) 2,531 (27.5)
2003 3,496 (23.1) 1,092 (18.4) 2,404 (26.1)
T stage .08
T1 6,296 (41.6) 2,417 (40.7) 3,879 (42.2)
T2 8,832 (58.4) 3,515 (59.3) 5,317 (57.8)
Grade , .001
Well differentiated, 2-4 759 (5.0) 333 (5.6) 426 (4.6)
Moderately differentiated, 5-7 13,867 (91.7) 5,439 (91.7) 8,428 (91.6)
Missing 502 (3.3) 160 (2.7) 342 (3.7)
No. of comorbidities , .001
0 10,245 (67.7) 4,129 (69.6) 6,116 (66.5)
1 3,298 (21.8) 1,240 (20.9) 2,058 (22.4)
2 998 (6.6) 354 (6.0) 644 (7.0)
$ 3 587 (3.9) 209 (3.5) 378 (4.1)
Age, years, mean (SD) 73.9 (5.5) 73.7 (5.5) 73.9 (5.5) .03
Race/ethnicity , .001
Non-Hispanic white 12,008 (79.4) 4,878 (82.2) 7,130 (77.5)
Non-Hispanic black 1,175 (7.8) 303 (5.1) 872 (9.5)
Hispanic 925 (6.1) 352 (5.9) 573 (6.2)
Other 550 (3.6) 249 (4.2) 301 (3.3)
Missing 470 (3.1) 150 (2.5) 320 (3.5)
Marital status .01
Not married 2,767 (18.3) 1,022 (17.2) 1,745 (19.0)
Married 10,231 (67.6) 4,086 (68.9) 6,145 (66.8)
Missing 824 (14.1) 5,923 (13.9) 9,196 (14.2)
Pretreatment primary care use .19
0-2 visits in prior year 2,991 (19.8) 1,135 (19.1) 1,856 (20.2)
3-5 visits in prior year 6,753 (44.6) 2,693 (45.4) 4.060 (44.1)
$ 6 visits in prior year 5,384 (35.6) 2,104 (35.5) 3,280 (35.7)
Primary care consultation .21
No 7,104 (47.0) 2,823 (47.6) 4,281 (46.6)
Yes 8,024 (53.0) 3,109 (52.4) 4,915 (53.4)
Radiation oncology consultation .008
No 10,805 (71.4) 4,309 (72.6) 6,496 (70.6)
Yes 4,323 (28.6) 1,623 (27.4) 2,700 (29.4)
(continued on following page)
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study to minimize the contribution from these potentially
confounding factors and exploited a natural variation in
reimbursement that occurred both within and between
urologists as a result of the inconsistent Medicare reim-
bursement policy.
Asecondreasonour findingsmaydiffer fromearlierstudies
is because the size and consistency of the reimbursement
changedifferedbetween thestudyperiods. Studiesnoting large
changes in treatment patterns examined a consistent
treatment-level reimbursement decrease of 65% over a 2-year
Table 1. Patient Characteristics According to Reimbursement Generosity Index of Urologists Prescribing GnRH Agonists
(continued)
Characteristic Overall (N = 15,128)
GnRH Agonist
Reimbursement
Less Than or Equal to
National Average
(n = 5,932)
GnRH Agonist
Reimbursement
Greater Than
National Average
(n = 9,196) P
Medical oncology consultation .04
No 14,603 (96.5) 5,703 (96.1) 8,900 (96.8)
Yes 525 (3.5) 229 (3.9) 296 (3.2)
Urology consultation .008
No 156 (1.0) 45 (0.8) 111 (1.2)
Yes 14,972 (99) 5,887 (99.2) 9,085 (98.8)
Rural residence , .001
No 14,835 (98.1) 5,768 (97.2) 9,067 (98.6)
Yes 293 (1.9) 164 (2.8) 129 (1.4)
SEER region , .001
Seattle 751 (5.0) 644 (10.9) 107 (1.2)
Connecticut 1,037 (6.9) 477 (8.0) 560 (6.1)
Detroit 1,270 (8.4) 108 (1.8) 1,162 (12.6)
Hawaii 163 (1.1) 105 (1.8) 58 (0.6)
Iowa 1,133 (7.5) 439 (7.4) 694 (7.5)
New Mexico 368 (2.4) 51 (0.9) 317 (3.4)
California 4,498 (29.7) 1,982 (33.4) 2,516 (27.4)
Utah 678 (4.5) 631 (10.6) 47 (0.5)
Georgia 332 (2.2) 27 (0.5) 305 (3.3)
Kentucky 1,212 (8.0) 670 (11.3) 542 (5.9)
Louisiana 1,233 (8.2) 340 (5.7) 893 (9.7)
New Jersey 2,453 (16.2) 458 (7.7) 1,995 (21.7)
Median income of patients’ communities, dollars , .001
2,506-35,031 3,574 (23.6) 1,495 (25.2) 2,079 (22.6)
35,051-46,079 3,817 (25.2) 1,660 (28.0) 2,157 (23.5)
46,084-60,668 3,563 (23.6) 1,351 (22.8) 2,212 (24.1)
60,669-200,008 3,596 (23.8) 1,205 (20.3) 2,391 (26.0)
Missing 578 (3.8) 221 (3.7) 357 (3.9)
Proportion of patient’s community without high school
education, %
.002
0-9.7 3,615 (23.9) 1,499 (25.3) 2,116 (23.0)
9.7-15.5 3,720 (24.6) 1,469 (24.8) 2,251 (24.5)
15.5-25.2 3,569 (23.6) 1,313 (22.1) 2,256 (24.5)
25.2-100 3,653 (24.1) 1,431 (24.1) 2,222 (24.2)
Missing 571 (3.8) 220 (3.7) 351 (3.8)
NOTE. Data are presented as No. (%) unless otherwise indicated. Reimbursement generosity index indicates GnRH agonist reimbursement relative to the
national average. P values calculated with t test for continuous variables and x2 test for binary/categorical variables.
Abbreviations: GnRH, gonadotropin-releasing hormone; SD, standard deviation.
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period. In our study, although average annual SEER-widedrug
reimbursements fluctuated as much as 17% for one of the
drugs, at the individual physician level, reimbursement
changesweremoremodest.Most physicians experienced little
change in their reimbursement on an annual basis. Of the
urologistswhoused the therapy consistently, 75%experienced
RGI changes—positive or negative—of less than 2.6% in any
given year. Still, we did not have access to the cost of GnRH
agonists usedby theurologists. Because physicianswouldhave
been responding to marginal costs (difference between cost
and reimbursement) rather than reimbursement alone, we
assumed that physicians with similar practice characteristics
and size might receive similar kinds of discounts and rebates
from pharmaceutical manufacturers or have similar access to
Table 2. Characteristics of Urologists Prescribing Primary GnRH Agonists
Characteristic
Overall
(N = 1,800)
GnRH Agonist
Reimbursement
Less than or Equal to
National Average
(n = 701)
GnRH Agonist
Reimbursement
Greater Than
National Average
(n = 1,099) P
Proportion of patients in practice receiving unnecessary
GnRH agonist, mean (SD)
0.3 (0.3) 0.3 (0.3) 0.3 (0.3) .56
Reimbursement generosity index, mean (SD) 2.9 (73.6) 237.0 (62.2) 28.4 (68.9) , .001
Years in practice .42
, 20 686 (38.1) 259 (36.9) 427 (38.9)
$ 20 1,114 (61.9) 442 (63.1) 672 (61.1)
Sex .41
Male 1,763 (97.9) 689 (98.3) 1,074 (97.7)
Female 37 (2.1) 12 (1.7) 25 (2.3)
US trained .29
No 298 (16.6) 108 (15.4) 190 (17.3)
Yes 593 (83.4) 593 (84.6) 909 (82.7)
Board certified .55
No 113 (6.3) 41 (5.8) 72 (6.6)
Yes 1,687 (93.7) 660 (94.2) 1,027 (93.4)
Medical school affiliation , .001
None 903 (50.2) 391 (55.8) 512 (46.6)
Some 854 (47.4) 294 (41.9) 560 (51.0)
Missing 43 (2.4) 16 (2.3) 27 (2.5)
Physician prostate panel size, prostate patients per year .45
0-20 1,195 (66.4) 474 (67.6) 721 (65.6)
21-37 454 (25.2) 175 (25.0) 279 (25.4)
$ 38 151 (8.4) 52 (7.4) 99 (9.0)
Practice type .03
Group practice 1,274 (70.8) 471 (67.2) 803 (73.1)
Solo practice 442 (24.6) 193 (27.5) 249 (22.7)
Missing 84 (4.7) 37 (5.3) 47 (4.3)
Proportion of minority patients, % , .001
, 6.1 668 (37.1) 295 (42.1) 373 (33.9)
6.2-19.5 522 (29.0) 211 (30.1) 311 (28.3)
$ 20 610 (33.9) 195 (27.8) 415 (37.8)
NOTE. Data are presented as No. (%) unless otherwise indicated. P values determined by t test for continuous variables and x2 test for binary/categorical
variables.
Abbreviations: GnRH, gonadotropin-releasing hormone; SD, standard deviation.
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third-party suppliers who could negotiate lower drug
costs29,37 and controlled our model accordingly. Nonetheless,
whether reimbursement shifted significantly enough to affect
marginal costs during our study period is unknown, although
none of the prior observational studies suggesting a strong
effect of reimbursement on GnRH agonist use measured
marginal costs either.7,8 Better efforts to capture marginal
costs are needed in future studies. To place our findings in the
context of the unfolding Medicare value initiatives, the global
payment changes incurred by the CMS initiative to align fee-
for-service payments with higher quality and greater value
(the Physician Feedback Program/Value-Based Payment
Modifier) resulted in payment cuts of 0.5% to 1% and bonuses
of up to 2%.38 Our study demonstrates that reimbursement
variation more than twice the current CMS penalties did not
seem to deter potentially inappropriate prescribing. Thus, if
small physician-level reimbursement changes have little effect
on shapingdesired patterns of care, itmaybemore efficient for
CMS to expand alternative payment models (eg, episode-
based payments) than to further tweak the current fee-for-
service schedule.
However, there are differences in the way reimbursement
cuts were experienced in our study compared with the CMS
Physician Feedback Program. In localized prostate cancer, any
decrease in reimbursement was coupled with the individual
administration of the drug. CMSpenalties are global, accrue to
the practice, and have been widely publicized. Whether and
how quickly a physician receives negative feedback for a
specific behavior—an important component of effective
behavior change—would be mediated by practice manage-
ment’s ability to link the behavior to the consequence and to
Table 3. Multilevel Regression Predicting Primary GnRH
Agonist Use
Factor Odds Ratio 95% CI
Reimbursement generosity index 1.00 1.00 to 1.00
Practice type
Group practice Reference
Solo practice 1.27 1.07 to 1.52
Missing 0.86 0.58 to 1.26
Physician prostate panel size, prostate
patients per year
, 20 Reference
21-37 0.75 0.65 to 0.86
$ 38 0.81 0.68 to 0.96
T stage
T1 Reference
T2 1.91 1.72 to 2.13
Grade
Well differentiated, 2-4 Reference
Moderately differentiated, 5-7 2.26 1.78 to 2.88
Missing 3.50 2.50 to 4.91
No. of comorbidities
0 Reference
1 1.40 1.24 to 1.57
2 1.43 1.18 to 1.72
$ 3 2.07 1.65 to 2.60
Age, years 1.78 1.38 to 2.30
Age, squared 1.00 1.00 to 1.00
Race/ethnicity
Non-Hispanic white Reference
Non-Hispanic black 1.42 1.17 to 1.73
Hispanic 1.25 1.00 to 1.56
Other 1.30 0.94 to 1.79
Missing 1.95 1.50 to 2.53
Radiation oncology consultation
No Reference
Yes 0.26 0.23 to 0.31
Medical oncology consultation
No Reference
Yes 0.88 0.65 to 1.19
Urology consultation
No Reference
Yes 5.62 3.19 to 9.90
(continued in next column)
Table 3. Multilevel Regression Predicting Primary GnRH
Agonist Use (continued)
Factor Odds Ratio 95% CI
Primary care consultation
No Reference
Yes 0.41 0.36 to 0.46
Constant 0.95 0.87 to 1.04
NOTE. Sample includes only patients (n = 15,128) of urologists who pre-
scribed GnRH agonists. The model also adjusts for urologists’ length of time
in practice, sex, training location, board certification status, medical school
affiliation, proportionofminority patients in practice, patients’marital status,
rural residence, community educational attainment, community income,
prior primary care use, year treated, and SEER region.
Abbreviation: GnRH, gonadotropin-releasing hormone.
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implement effective remediation. We cannot assess the
mediating effect of practice management, and this should be
the subject of future studies that seek tounderstandhowglobal
payment adjustmentswork effectively. Future research should
also isolate the effects of the timing of the reimbursement
penalties. CMS penalties lag performance by 2 years. We
presume reimbursement cuts were realized more quickly in
our study, but time topayment canvary on the basis of practice
and carrier factors that were not measured in our admin-
istrative claims. Finally, we do not know the degree to which
social influences facilitate behavior change in a global payment
cut. Although 2015 CMS penalties were equivalent to less
than $345 per physician,38 they accrued to the practice,
and the ways practices identify and manage outliers are
unknown.
Our study has limitations. First, we were unable to control
for the proportionof a physician’s patients whowere in fee-for
service Medicare. However, few urology practices treat high
proportions of Medicare patients, and urologists maintained
stable portions of Medicare patients during this time.32-34
Second, we conducted our study among urologists. Much of
cancer care is delivered by medical and radiation oncologists,
and our results may not be generalizable to these providers.
Future studies should address these groups specifically to
compare how reimbursement changes, both small and large,
affected their prescribing of GnRH agonists to complete our
understanding of the clinical and practice contexts in which
reimbursement does or does not change clinical decision
making. Last, although rates of GnRH agonist use in our study
mirror trends reported elsewhere,7,8 our study is limited to
Medicare patients older than 66 years who were treated by
urologists.
Although policymakers and payers may view reimburse-
ment change as a promising strategy to reduce overuse,39 this
was not necessarily the case for urologists experiencing
average treatment-level variations in GnRH agonist
reimbursement of 2.6% in our large, national sample of men
with localized prostate cancer. Multiple sensitivity analyses
supported our finding that reimbursement changes were not
associated with practice patterns. Policy changes being
implemented in 2015 also result in small reimbursement cuts
to physicians.40 Our findings suggest these changes may not
influence patterns of care; however, additional research to
identify the potentially nuanced way in which physicians
respond to reimbursement changes is needed to further
inform policy decisions.
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Appendix
Reimbursement Generosity Calculation
The reimbursement generosity index was calculated as follows:
Rit ¼
g2gði;tÞPitg 2 PtgWtg
g2gði;tÞWtg
where Pitg is the average reimbursement for patients receiving GnRH agonist g prescribed by provider i in year t, and Ptg is the SEER
average reimbursement of GnRH agonist g in year t.Wtg, the weight for GnRH agonist g, is the ratio of SEER-wide spending on that regimen
to total spending on all GnRH agonists. Each GnRH agonist regimen was dose standardized by converting each instance of GnRH agonist in
use on separate days to a monthly dosing regimen. Intended duration was determined from the unit designation of the “carrier miles/time/
units/serv count” field in carrier claims or the “revenue center unit count” field in outpatient claims. Claims for 12-month implant were
assumed to represent 12 months of therapy regardless of unit designation. The alternate RGIs considered in the sensitivity analyses treated
all prostate cancer treatments combined (surgery, radiation, and surveillance) as a single treatment modality. In analyses including
urologists who did not prescribe GnRH agonists, we considered the RGI to be equal to 0.
Control Variables
Patient-level factors
Disease severity included tumor stage and grade, categorized as low (Gleason score 2 to 4) or intermediate (Gleason score 5 to 7).
Comorbidities were measured by the National Cancer Institute Comorbidity Index (Klabunde CN, et al: Ann Epidemiol 17:584-590, 2007).8
Patient demographics included age, race/ethnicity, and marital status (married/living with partner v single, widowed, or divorced, or missing).
Health care use included prior primary care use (any claim in the 12 months before diagnosis), (Feldstein PJ: Health Policy Issues: An
Economic Perspective [4th ed], 2007) specialist consultation (three binary variables indicating more than one prostate-related claim filed by a
radiation oncologist, urologist, or medical oncologist between diagnosis and the earliest of first treatment date or 12 months, Jang TL, et al:
Arch Intern Med 170:440-450, 2010), and primary care consultation (more than one visit to the same primary care physician occurring in both
the 12months before diagnosis and the window between diagnosis and treatment, Jang TL, et al: Arch InternMed 170:440-450, 2010).We also
controlled for SEER region, collapsed by state, rurality of patient’s residence (urban v rural), and community deprivation (quartiles of median
income and proportion of adults with, 12 years of education in the patients’ ZIP code of residence, Fiscella K, et al: Med Care 39:8-14, 2001).
Provider-level factors
Using data from the American Medical Association and SEER Hospital files, we measured the following: physician sex; time in practice;
medical professionalization (Reid RO, et al: Arch Intern Med 170:1442-1449, 2010; Wright JD, et al: J Clin Oncol 29:3408-3418, 2011)3
defined as board certification (yes or no) and degree of affiliation with an academic institution (categorical); training location (US versus
foreign); panel size (number of patients with prostate cancer per year per urologist); practice type (solo, group practice, or missing); and
proportion of minority Medicare patients within a practice (quartiles, Shahinian VB, et al: J Clin Oncol 25:5359-5365, 2007). We controlled
for national trends by including variables for each year of the study.
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No prior cancer
(n = 134,802)
Missing or invalid
date of diagnosis (n = 489) 
Reported at autopsy,
death, or nursing home
(n = 174) < 66 years of age
at diagnosis (n = 46,631) 
Without continuous
Parts A and B Medicare
 (n = 8,039) 
Likely to have
complete claims
 (n = 55,829) 
With HMO
coverage (n = 23,640) 
With multiple cancers
 (n = 82) With invalid death date
 (n = 4)
Missing stage (n = 1,491)
Died within 12 months
of diagnosis (n = 2,514) 
Treatment 
can be ascertained
 (n = 51,738) 
With low- or
intermediate-risk cancer
 (n = 36,242) 
Had nonphysician
treating provider
 (n = 225) 
Less than 5 years life
expectancy (n = 857) 
Had no treatment
claims (n = 3,432) 
Treated by other
specialty (n = 2,070) 
Non-ADT
using urologists (n = 323)  
Treated  by
radiation oncologists
 (n = 12,868) 
Missing data (n = 1)
Matched
treating physician
 (n = 31,728)  
Patients (n = 16,789)
treated by
urologists  (n = 2,213)
Patients (n = 15,128)
treated 
by urologists (n = 1,800) 
Men with 
adenocarcinoma of the 
prostate diagnosed in  
2000-2003 (N = 159,435) 
FIG A1. Cohort exclusions. ADT, androgen-deprivation therapy; HMO,
health maintenance organization.
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Table A1. Treatment Claims
Treatment ICD-9 Codes CPT/HCPCS Codes
Androgen deprivation
therapy (GnRH agonist)
J0128, J1950, J9202, J9217, J9218, J9219, J9225, J9226,
J3315, C9216, C9430, or S0165
Nonsurveillance prostate
treatment
60, 60.1, 60.21, 60.29, 60.3, 60.4, 60.5, 60.61-60.69, 62.3,
62.4, 62.41, 62.42, 92.2, 92.21, 92.22, 92.23, 92.24,
92.25, 92.26, 92.27, 92.28, 92.29, 99.25, V58.0, V58.1x,
V66.1, V66.2, V67.1, V67.2
00865, 54520, 54522, 54530, 54535, 54690, 55801,
55810, 55812, 55815, 55821, 55831, 55840, 55842,
55845, 55860, 55866, 55873, 55875, 55876, 76873,
77301, 77305, 77310, 77315, 77321, 77326, 77327,
77328, 77338, 77371, 77372, 77373, 77380, 77381,
77402, 77403, 77404, 77406, 77407, 77408, 77409,
77411, 77412, 77413, 77414, 77416, 77418, 77423,
77432, 77435, 77520, 77522, 77523, 77525, 77750-
77760, 77761, 77762, 77763, 77774, 77775, 77776,
77777, 77778, 77779, 77780, 77781, 77782, 77783,
77784, 77785, 77786, 77787, 77789, 77790, 77791-
77798, 77799, G0356, J1675, J9000-J9164, 0073T,
0082T, 0083T, 0182T, 4164F, A9527, C1715, C1716,
C1717, C1719, C1728, C2634, C2635, C2636, C2637,
C2638, C2639, C2640, C2641, C2642, C2643, C2698,
C2699, C9725, G0174, G0178, G0251, G0339, G0340,
J1050, J1051, J9165, J9166-J9201, J9203-J9216, J9220-
J9224, J9227- J9998, J9999, Q0083-Q0085, Q3001,
S0175, S9560, C2616
Abbreviations: CPT, current procedural terminology; GnRH, gonadotropin-releasing hormone; HCPCS, Healthcare Common Procedure Coding System; ICD-9:
International Classification of Diseases, 9th Revision.
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